• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

Janssen

multiple-myeloma
Posted inNew Drugs, Oncology, Rare/Orphan Diseases, Regulatory

Tecvayli: New Drug for Multiple Myeloma

by Mark Gubar August 24, 2022September 8, 2022

Teclistamab by Johnson & Johnson is a new hope for refractory or relapsing multiple myeloma.

coronavirus
Posted inCOVID-19, Infections, Research

Three Billion Omicron Cases

by Timur Burkhanayev December 25, 2021April 11, 2024

Omicron, a new variant of the SARS-CoV-2 coronavirus, will infect nearly 40% of the world’s population.

Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Vyvgart: New Drug to Treat Myasthenia Gravis

by Tanya von Reuss December 19, 2021September 8, 2022

Efgartigimod developed by Argenx is a strong competitor to Soliris.

coronavirus
Posted inCOVID-19, Infections, Research

Omicron Variant: Latest Scientific News, Findings, Evidence, and Developments

by Nik Resovski and Timur Burkhanayev December 17, 2021April 11, 2024

Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.

Posted inAutoimmune Diseases, New Drugs, Regulatory

Zeposia: New Drug for Ulcerative Colitis

by Julia Mardi June 2, 2021September 8, 2022

Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Ponvory: Another Drug for Multiple Sclerosis

by Mark Gubar May 17, 2021September 8, 2022

Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis

by Julia Mardi April 21, 2021September 8, 2022

Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.

Posts pagination

1 2 Older posts
BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×